Five Appendices 3Y, “Change of Director’s Interest Notice”, have been released to announce the entitlement right offers taken up by Imagion Directors.
Read the Appendices 3Y:
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)